Expert faculty discuss the role of functional molecular imaging to optimize treatment decision making in metastatic breast cancer.
Oct 31, 2017
Oct 31, 2018
Lee Lokey, MDprIME Oncology
Atlanta, Georgia, United States
Geraldine Gebhart, MDInstitut Jules Bordet
Alessandra Gennari, MD, PhDGalliera Hospital
- What is functional molecular imaging?
- Tumor heterogeneity and implications in selection of treatment for metastatic disease
- Results of recent trials of functional molecular imaging
- Future directions
This educational activity is designed for surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with breast cancer.
Upon completion of this educational activity, participants should be able to:
- Assess the impact of tumor heterogeneity on prognosis and treatment selection in breast cancer
- Describe current principles and techniques of molecular imaging in breast cancer that can allow for individualized treatment selection
- Identify emerging molecular imaging techniques for breast cancer currently being investigated in clinical trials
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.